Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 2, 2003, Pages 139-146

  Cusack, Barry J ^a,b,c   Musser, Beth ^a   Gambliel, Hervé ^a,b   Hadjokas, Nicholas E ^a   Olson, Richard D ^a,b,c  

^a Boise VA Medical Center   (United States)

^b Mountain States Tumor and Medical Research Institute   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracyclines; Dexrazoxane; Doxorubicin; Doxorubicinol; Rat

Indexed keywords

DOXORUBICIN; DOXORUBICINOL; RAZOXANE;

AGE; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG TISSUE LEVEL; HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0037325413     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0544-1     Document Type: Article

References (47)

1. Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-53
2. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. New Engl J Med 339:900-905
3. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717
4. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels MR (1977) Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17-23
5. Praga C, Beretta G, Vigo PL, et al (1979) Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 63:827-834
6. Robert J, Hoerni B (1983) Age-dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 43:4467-4469
7. Robert J, Bui NB, Vrignaud P (1987) Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 31:695-699
8. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, Slater W, Blum R, Muggia F (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. New Engl J Med 319:745-752
9. Herman EH, Ferrans VJ, Young RSK, Hamlin RL (1988) Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res 48:6918-6925
10. Imondi AR, Della Torre P, Mazue G, Sullivan TM, Robbins TL, Hagerman LR, Podesta A, Pincirolli G (1996) Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 56:4200-4204
11. Villani F, Galimberti M, Monti E, Cova D, Lanza E, Rozza-Dionigi A, Favalli L, Poggi P (1990) Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol Appl Pharmacol 102:292-299
12. Rosing H, ten Bokkel Huinink WW, van Gijn R, Rombouts RF, Bult A, Beijnen JH (1999) Comparative open, randomized, crossover bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). Eur J Drug Metab Pharmacokinet 24:69-77
13. Vestal RE, Cusack BJ (1990) Pharmacology and aging. In: Schneider EL, Rowe JW (eds) Handbook of the biology of aging. Academic Press, New York, pp 349-383
14. Cusack BJ, Young SP, Olson RD (1995) Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cancer Chemother Pharmacol 35:213-218
15. Cusack BJ, Tesnohlidek DA, Loseke VL, Vestal RE, Brenner DE, Olson RD (1988) Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 22:294
16. Cusack BJ, Young SP, Loseke VL, Hurty MR, Olson RD (1992) Effect of low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother Pharmacol 30:145-150
17. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradisher WJ, et al (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 10:3333-3355
18. Colombo T, Donelli MG, Urso R, Dallarda S, Bartosek I, Guaitani A (1989) Doxorubicin toxicity and pharmacokinetics in old and young rats. Exp Gerontol 24:159-171
19. Cusack BJ, Young SP, Vestal RE, Olson RD (1997) Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin in the rat. Cancer Chemother Pharmacol 39:505-512
20. Bielack Ss, Ertmann R, Kempf-Bielack B, Winkler K (1996) Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 32A:1652-1660
21. Cusack BJ, Young SP, Sellers D, Trajovska B, Mills JR, Vestal RE, Olson RD (1997) Effect of aging on chronic daunorubicin cardiotoxicity (abstract). J Investig Med 45:266A
22. Sweatman TW, Israel M (1987) Comparative metabolism and elimination of adriamycin and 4′-epiadriamycin in the rat. Cancer Chemother Pharmacol 19:201-206
23. Ballet F, Vrignaud P, Robert J, Rey C, Poupon R (1987) Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemother Pharmacol 19:240-245
24. LeBot MA, Bégué JM, Kernalegeun D, Robert J, Ratanasvanh D, Airiau J, Riché C, Guillouzo A (1988) Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochem Pharmacol 37:3877-3887
25. Vaidyanathan S, Boroujerdi M (2000) Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin. Cancer Chemother Pharmacol 46:93-100
26. Baldwin JR, Phillips BA, Overmyer SK, Hatfield NZ, Narang PK (1992) Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. Cancer Chemother Pharmacol 30:433-438
27. Sparano JA, Speyer J, Gradisher WJ, Liebes L, Rajeshwari S, Mendoza S, Fry D, Egorin MJ (1999) Phase 1 trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol 17:880-886
28. Hochster H, Liebes L, Wasler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, Speyer JL (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725-1730
29. Danesi D, del Tacca M, Bernardini C, Penco S (1987) Exogenous doxorubicinol induces cardiotoxic effects in rats. Eur J Cancer Clin Oncol 23:907-913
30. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Chang BK, Cusack BJ, Boucek RJ (1988) Doxorubicin cardiotoxicity may be caused by its metabolite doxorubicinol. Proc Natl Acad Sci U S A 85:3585-3589
31. Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: a correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262:15851-15856
32. Wang G-X, Wang Y-X, Zhou X-B, Korth M (2001) Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur J Pharmacol 423:99-107
33. Minotti G, Recalcati S, Mordente A, Liberi G, Califiore AM, Mancuso C, Presiosi P, Cairo G (1998) The secondary alcohol metabolites of doxorubicin irreversibly inactivate aconitase/ iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541-555
34. Forrest GL, Gonzalez B, Tseng W, Li X, Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity. Cancer Res 60:5158-5164
35. Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS, Olson RD (2002) Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun 291:433-438
36. Wilkinson PM, Mawer GE (1974) The persistence of adriamycin in man and rat. Br J Clin Pharmacol 1:241-247
37. Benjamin RS, Riggs CE, Bachur NR (1973) Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14:592-600
38. Wilkinson PM, Israel M, Pegg WJ, Frei E 3rd (1979) Comparative metabolism and excretion of adriamycin in man, monkey, and rat. Cancer Chemother Pharmacol 2:121-125
39. Loveless H, Arena E, Felsted RL, Bachur NR (1978) Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 38:593-598
40. Ahmed NK, Felsted RL, Bachur NR (1978) Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers. Biochem Pharmacol 27:2713-2719
41. Schmucker DL (2001) Liver function and phase 1 drug metabolism in the elderly. Drugs Aging 18:837-851
42. Kato R, Takanaka A (1968) Metabolism of drugs in old rats: II. Metabolism in vivo and effects of drugs in old rats. Jpn J Pharmacol 18:389-396
43. Durnas C, Cho-Ming L, Cusack BJ (1990) Hepatic drug metabolism and aging. Clin Pharmacokinet 19:359-389
44. Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076-3086
45. Minotti G, Cairo G, Monti E (1999) Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 13:199-212
46. Batist G, Ramakrishnan G, Rao C, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair M, Hoelzer K, Tkaczuk K, Park Y, Lee L (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxo-rubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial for metastatic breast cancer. J Clin Oncol 19:1444-1454
47. Behnia K, Boroujerdi M (1999) Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. J Pharm Pharmacol 51:1275-1282